secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-179062
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Therapy Designation to TERN-701; Merck acquisition mentioned in press release
--------------------------------------------------------------------------------

- FDA Breakthrough Therapy Designation for TERN-701 in Ph+ CML-CP patients without T315I mutation, previously treated with 2+ TKIs.
- Designation based on CARDINAL Phase 1/2 data: encouraging major molecular response and deep molecular response rates at week 24.
- TERN-701 safety profile: majority of adverse events low grade; low severe adverse events and discontinuations.
- Press release also notes recent agreement for Merck to acquire Terns (Nasdaq: TERN).
- CEO Amy Burroughs cites BTD and Merck deal as potential acceleration to pivotal trial and patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312526179062/0001193125-26-179062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312526179062/d122087d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-179062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer